PegBio Co., Ltd. (HKG:2565)

Market Cap	4.08B
Revenue (ttm)	n/a
Net Income (ttm)	-301.33M
Shares Out	385.96M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	532,000
Average Volume	7,251,100
Open	10.58
Previous Close	10.58
Day's Range	10.58 - 11.10
52-Week Range	10.44 - 13.50
Beta	n/a
RSI	n/a
Earnings Date	n/a

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. The company’s products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of T2DM and obesity; and PB-201, a candidate for the treatment of T2DM. The company’s PB-718 that is in Phase IIb clinical trials for the treatment non-alcoholic lipids fatty liver disease; and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2008
• Employees: 53
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2565

Financial Performance

Financial numbers in CNY